ARTICLE | Clinical News
Fovista: Phase IIa started
August 18, 2014 7:00 AM UTC
Ophthotech began an open-label, U.S. Phase IIa trial to evaluate Fovista in combination with anti-VEGF therapy in about 100 patients with wet AMD. Fovista is in Phase III testing to treat wet AMD, with top-line data expected in 2016. ...